We are live on ! Find out more
ENZ

Enzo Biochem, Inc.

Delisted

ENZ was delisted on the 17th of April, 2025.

50 hedge funds and large institutions have $34.8M invested in Enzo Biochem, Inc. in 2013 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 15 increasing their positions, 13 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 13

8% more capital invested

Capital invested by funds: $32.2M → $34.8M (+$2.62M)

4% less funds holding

Funds holding: 5250 (-2)

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

97% less call options, than puts

Call options by funds: $6K | Put options by funds: $188K

Holders
50
Holders Change
-2
Holders Change %
-3.85%
% of All Funds
1.45%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
15
Reduced
13
Closed
6
Calls
$6K
Puts
$188K
Net Calls
-$182K
Net Calls Change
-$96K
Name Holding Trade Value Shares
Change
Change in
Stake
Two Sigma Advisers
26
Two Sigma Advisers
New York
$88K +$73.9K +29,800 New
State Street
27
State Street
Massachusetts
$69K
Citadel Advisors
28
Citadel Advisors
Florida
$63K +$20.8K +8,386 +64%
Barclays
29
Barclays
United Kingdom
$52K +$48.6K +19,580 +297%
U
30
UBS
Switzerland
$50K +$17.4K +7,000 +70%
Jacobs Levy Equity Management
31
Jacobs Levy Equity Management
New Jersey
$48K -$21.6K -8,700 -34%
FTIOP
32
Fiduciary Trust International of Pennsylvania
Pennsylvania
$46K
PPA
33
Parametric Portfolio Associates
Washington
$45K -$5.99K -2,415 -14%
GC
34
Guggenheim Capital
Illinois
$44K +$2.22K +896 +6%
Group One Trading
35
Group One Trading
Illinois
$39K +$15.4K +6,200 +87%
T. Rowe Price Associates
36
T. Rowe Price Associates
Maryland
$38K
BA
37
BlackRock Advisors
Delaware
$23K
LTFS
38
Ladenburg Thalmann Financial Services
Florida
$11K
Wells Fargo
39
Wells Fargo
California
$11K +$5.08K +2,048 +136%
TJHA
40
Thomas J. Herzfeld Advisors
Florida
$9K
Bank of America
41
Bank of America
North Carolina
$4K -$18.2K -7,341 -85%
BNP Paribas Financial Markets
42
BNP Paribas Financial Markets
France
$3.29K +$2.79K +1,127 New
HCM
43
Horrell Capital Management
Arkansas
$3K
AIG
44
American International Group
New York
$2.92K
Ameriprise
45
Ameriprise
Minnesota
$2K
CPA
46
Cowen Prime Advisors
New York
$1K
HI
47
Hudock Inc
Pennsylvania
$1K
TRCT
48
Tower Research Capital (TRC)
New York
$1K +$878 +354 +398%
Manulife (Manufacturers Life Insurance)
49
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$4
LMF
50
LMR Master Fund
Cayman Islands
-$435K -172,696 Closed

ENZ Hedge Fund Activity: Q4 2013 in Review

50 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q4 2013, worth a combined $34.8M — up 8.1% from $32.2M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of ENZ and 4 opened new positions — a net loss of 2 holders — while 13 trimmed existing stakes and 15 added.

The largest buyer was Platte River Capital, opening a new position worth an estimated $1.32M. The largest seller was RA Capital Management, cutting an estimated $2.68M.

  • 50 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q4 2013, down from 52 in Q3 2013.
  • Funds reported $34.8M of Enzo Biochem, Inc. stock for Q4 2013, up 8.1% quarter-over-quarter.
  • 4 funds opened new Enzo Biochem, Inc. positions in Q4 2013 and 6 closed out, a net change of -2 holders.
  • The largest Enzo Biochem, Inc. buyer in Q4 2013 was Platte River Capital, an estimated $1.32M added.
  • The largest Enzo Biochem, Inc. seller in Q4 2013 was RA Capital Management, an estimated $2.68M sold.

Based on aggregated 13F filings for Q4 2013.